This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Keryx: Perifosine Colon Cancer Trial Fails

NEW YORK ( TheStreet) -- Keryx Pharmaceuticals (KERX - Get Report) announced Monday the failure of its experimental colon cancer drug perifosine.

Keryx shares fell 56% TO $2.16 in Monday pre-market trading. Shares of Aeterna Zentaris (AEZS - Get Report), which own ex-U.S. rights to perifosine, were down 63% to 79 cents.

The failed phase III study enrolled 468 patients with advanced colon cancer, randomizing them to treatment with perifosine plus Roche's Xeloda or a placebo plus Xeloda. Perifosine failed to improve overall survival, the primary endpoint of the study, Keryx said.

"We are all extremely disappointed with the results of the study," said Keryx CEO Ron Bentsur, adding that the company will evaluate whether or not to continue a separate phase III study of perifosine in multiple myeloma.

Not everyone is surprised at perifosine's failure. University of Chicago oncologist Dr. Mark Ratain and I predicted the negative outcome of the colon cancer study last October.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AEZS $0.57 0.00%
KERX $11.41 0.00%
AAPL $130.28 0.00%
FB $81.53 0.00%
GOOG $565.06 0.00%


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs